BioCentury | May 30, 2011
Finance

Europe's Iceberg 2011: Unlocking hidden value

...Serono S.A. Merck KGaA (Xetra:MRK) $13,200 2011 Crucell N.V. Johnson & Johnson (NYSE:JNJ) $2,400 2008 Speedel...
BioCentury | Jul 12, 2010
Strategy

Biogen Idec's Agenda

...mAb against integrin alpha(4)beta(7) receptor in Phase II for ulcerative colitis and Crohn's disease 2008 Speedel...
BioCentury | May 31, 2010
Finance

Performance Counts

...in osteoarthritis of the knee, with results due this year. Other winners included investors in Speedel...
...Aliskiren is marketed in the U.S. as Tekturna and in the EU as Rasilez . Speedel...
...peptides and peptidomimetics KuDos Pharmaceuticals Ltd. AstraZeneca plc (LSE:AZN; NYSE:AZN) $210 $53.9 Biology: DNA repair Speedel...
BioCentury | Aug 10, 2009
Finance

Hope springs eternal

...also of import for Lloyd-Harris (see BioCentury, Aug. 3) . "They're trying to copy the Speedel...
...as markets improved and there was more good news, then they raised money," he noted. Speedel...
BioCentury | Jul 27, 2009
Clinical News

Tekturna HCT Aliskiren/hydrochlorothiazide regulatory update

...a renin inhibitor approved in over 70 countries. The product was developed in collaboration with Speedel...
BioCentury | Jul 20, 2009
Clinical News

Rasilez aliskiren regulatory update

...as Tekturna, is approved in over 70 countries. The product was developed in collaboration with Speedel...
BioCentury | Mar 2, 2009
Clinical News

Rasilez HCT aliskiren/hydrochlorothiazide regulatory update

...indication. The product was developed in collaboration with Speedel, which is being acquired by Novartis. Speedel...
BioCentury | Feb 23, 2009
Clinical News

Rasilez aliskiren regulatory update

...seek medical attention. Rasilez, which is approved to treat hypertension, was developed in collaboration with Speedel...
BioCentury | Feb 9, 2009
Finance

Ebb & Flow

...the purchase of the pulmonary business of Nektar Therapeutics (NASDAQ: NKTR), and to take out Speedel...
BioCentury | Feb 2, 2009
Strategy

Valuing the upside

...surgical intervention to treat angina. Looking at one potential comparable - last year's acquisition of Speedel...
...deal was done last July. Novartis paid about CHF1 billion ($998 million) for the biotech. Speedel...
...and 1Q08 sales of $28 million, for an annual run rate of $112 million. However, Speedel...
Items per page:
1 - 10 of 203
BioCentury | May 30, 2011
Finance

Europe's Iceberg 2011: Unlocking hidden value

...Serono S.A. Merck KGaA (Xetra:MRK) $13,200 2011 Crucell N.V. Johnson & Johnson (NYSE:JNJ) $2,400 2008 Speedel...
BioCentury | Jul 12, 2010
Strategy

Biogen Idec's Agenda

...mAb against integrin alpha(4)beta(7) receptor in Phase II for ulcerative colitis and Crohn's disease 2008 Speedel...
BioCentury | May 31, 2010
Finance

Performance Counts

...in osteoarthritis of the knee, with results due this year. Other winners included investors in Speedel...
...Aliskiren is marketed in the U.S. as Tekturna and in the EU as Rasilez . Speedel...
...peptides and peptidomimetics KuDos Pharmaceuticals Ltd. AstraZeneca plc (LSE:AZN; NYSE:AZN) $210 $53.9 Biology: DNA repair Speedel...
BioCentury | Aug 10, 2009
Finance

Hope springs eternal

...also of import for Lloyd-Harris (see BioCentury, Aug. 3) . "They're trying to copy the Speedel...
...as markets improved and there was more good news, then they raised money," he noted. Speedel...
BioCentury | Jul 27, 2009
Clinical News

Tekturna HCT Aliskiren/hydrochlorothiazide regulatory update

...a renin inhibitor approved in over 70 countries. The product was developed in collaboration with Speedel...
BioCentury | Jul 20, 2009
Clinical News

Rasilez aliskiren regulatory update

...as Tekturna, is approved in over 70 countries. The product was developed in collaboration with Speedel...
BioCentury | Mar 2, 2009
Clinical News

Rasilez HCT aliskiren/hydrochlorothiazide regulatory update

...indication. The product was developed in collaboration with Speedel, which is being acquired by Novartis. Speedel...
BioCentury | Feb 23, 2009
Clinical News

Rasilez aliskiren regulatory update

...seek medical attention. Rasilez, which is approved to treat hypertension, was developed in collaboration with Speedel...
BioCentury | Feb 9, 2009
Finance

Ebb & Flow

...the purchase of the pulmonary business of Nektar Therapeutics (NASDAQ: NKTR), and to take out Speedel...
BioCentury | Feb 2, 2009
Strategy

Valuing the upside

...surgical intervention to treat angina. Looking at one potential comparable - last year's acquisition of Speedel...
...deal was done last July. Novartis paid about CHF1 billion ($998 million) for the biotech. Speedel...
...and 1Q08 sales of $28 million, for an annual run rate of $112 million. However, Speedel...
Items per page:
1 - 10 of 203